In the burgeoning RNAi sector, a handful of companies are working to develop the technology into a source of human therapeutics. Only one — Sirna Therapeutics — has said that it expects to have an RNAi drug ready for clinical trials next year.
But now, a Philadelphia-based start-up is pushing into the foreground with a seasoned biotech player in front and a even more ambitious timeline than its bigger rival.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.